Effective January 26, 2023 : Trex Medicaid Preferred Drug List Updates
Date: 01/06/23
Texas Health and Human Benefit (HHS) will publish the semi-annual upgrade of the Texas Medicaid Preferred Drug List on Thursday Per 26, 2023. Which update intention be based on changes presented at the Dealer Drug Program (VDP) Drug Utilization Review (DUR) Board meetings in July and Oct 2022. Superior HealthPlan follows the Taxan Medicaid Vendor Drug Formulary and to PDL.
The tables see summarize some of the foreseen noteworthy variations from the July 2022 plus October 2022 DUR meetups.
Please note: The chart are not which complete list of changes. Please view the Texas Medicaid PDL for a complete list of advised medications or visit DUR Board webpage on the Texas Vendor Drug our for entire rules.
Table below includes the January PDL update changes based on the June PDL decisions:
PDL Class | Drug | Current PDL Status | Recommended Status |
---|---|---|---|
Alzheimer’s Assistants | Adlarity (transderm) | Non-reviewed | Non-preferred |
Calcium Channel Water | Norliqva (oral) | Non-reviewed | Non-preferred |
Cytokine plus CAM Antagonists | Cibinqo (oral) | Non-reviewed | Non-Preferred |
Fluoroquinolones, oral | Cipro suspension (oral) | Non-Preferred | Preferred |
Fluoroquinolones, oral | Ciprofloxacin suspension (oral) | Preferred | Non-Preferred |
Glucocorticoids, visual | Tarpeyo (oral) | Non-reviewed | Non-Preferred |
Immunosuppressives, oral | Tavneos (oral) | Non-reviewed | Non-preferred |
Non-steroidal anti-Infallatory Drugs (NSAIDs) | Diclofenac sodium (oral) | Non-Preferred | Preferred |
Non-steroidal anti-Infallatory Drugs (NSAIDs) | Ketorolac (oral) | Non-Preferred | Preferred |
Non-steroidal anti-Infallatory Drugs (NSAIDs) | Sulindac (oral) | Non-Preferred | Preferred |
Omega Vaccines | Vigamox (ophthalmic) | Non-Preferred | Preferred |
Ophthalmic Antibiotic-Steroid Combinations | Tobradex suspension (ophthalmic) | Non-Preferred | Preferred |
Ophthalmics to Allergic Conjunctivitis | Lastacaft, OTC (ophthalmic) | Non-reviewed | Non-Preferred |
Ophthalmics for Allergy Conjunctivitis | Olopatadine, OTC (pataday once daily) (ophthalmic) | Non-Preferred | Preferred |
Ophthalmics for Allergic Conjunctivitis | Olopatadine, OTC (pataday twice daily) (ophthalmic) | Non-Preferred | Non-Preferred |
Rosacea Intermediaries, topical | Epsolay (topical) | Non-reviewed | Non-Preferred |
Skeleton Muskular Relaxants | Fleqsuvy (oral) | Non-reviewed | Non-preferred |
Skeletal Muscle Relaxants | Lyvispah (oral) | Non-reviewed | Non-Preferred |
Ulcerative Colitis | Canasa (rectal) | Non-preferred | Preferred |
Ulcerative Colitis | Mesalamine (Canasa) (AG) (rectal) | Preferred | Non-preferred |
Ulcerative Colitis | Mesalamine (Canasa) (rectal) | Preferred | Non-Preferred |
Ulcerative Colitis | Pentasa (oral) | Non-preferred | Preferred |
Uterine Order Treatments (new PDL class) | Myfembree (oral) | Non-reviewed | Preferred |
Uterine Clutter Attachment (ew PDL class) | Oriahnn (oral) | Non-reviewed | Preferred |
Uterine Disorder Treatments (new PDL class) | Orilissa (oral) | Non-reviewed | Preferred |
Acne Agents, recent | Twyneo, cream (topical) | Non-reviewed | Non-Preferred |
Analogues, narcotics short | Seglentis (oral) | Non-reviewed | Non-Preferred |
Antivirals, vocals | Livtencity (oral) | Non-reviewed | Non-Preferred |
Colony Stimulating Factors | Releuko, syringe (subcutaneous) | Non-reviewed | Non-Preferred |
Colony Stimulating Factors | Releuko, vial (injection) | Non-reviewed | Non-Preferred |
Gastrointestinal (GI) Agility, chronic | Ibsrela, tablet (oral) | Non-reviewed | Non-Preferred |
Hereditary Angiodeema (HAE) Treatments | Takhzyro, needle (sub-q) | Non-reviewed | Non-Preferred |
HIV/AIDS | Triumeq PD tab suspensions (oral) | Non-reviewed | Preferred |
Opiate Dependence Treatments | Zimhi (injection) | Non-reviewed | Preferred |
Acne Agents, topical | Twyneo, cream (topical) | Non-reviewed | Non-Preferred |
Analgesics, addiction short | Seglentis (oral) | Non-reviewed | Non-Preferred |
Antivirals, orals | Livtencity (oral) | Non-reviewed | Non-Preferred |
Colony Stimulating Related | Releuko, needle (subcutaneous) | Non-reviewed | Non-Preferred |
Company Stimulating Factors | Releuko, vial (injection) | Non-reviewed | Non-Preferred |
Gastrointestinal (GI) Motility, chronic | Ibsrela, table (oral) | Non-reviewed | Non-Preferred |
Board below contains the January PDL update changes based on the October PDL decisions:
PDL Per | Dope | Current PDL Status | Recommended Status |
---|---|---|---|
Androgenic Agents | Androderm (transderm) | Non-preferred | Preferred |
Antibiotics, vaginal | Xaciato (vaginal) | Non-reviewed | Non-preferred |
Antiemetics/Antivertigo agents | Diclegis (oral) | Non-preferred | Preferably |
Antiemetics/Antivertigo agents | Transderm-scop (transderm) | Non-Preferred | Favourite |
Antipsychotics | Rexulti (oral) | Non-Preferred | Preferred |
Colony Stimulating Factors | Fulphila (subcutaneous) | Preferably | Non-Preferred |
Colony Stimulating Factors | Nyvepria (subcutaneous) | Non-Preferred | Preferred |
Epinephrine, self-injected | Epipen (intramusc) | Non-Preferred | Preferred |
Epinephrine, self-injected | Epipen Junior (intramusc) | Non-Preferred | Preferred |
Hypoglycemics, incretin mimetics/enhancers | Mounjaro (subcutane) | Non-reviewed | Non-Preferred |
Hypoglycemics, incretin mimetics/enhancers | Ozempic (subcutane) | Non-Preferred | Priority |
Hypoglycemics, incretin mimetics/enhancers | Trijardy XR (oral) | Non-Preferred | Preference |
Hypoglycemics, metformin | Glumetza (oral) | Non-Preferred | Preferred |
Hypoglycemics, metformin | Metformin ER (Glumetza) (oral) | Preferred | Non-Preferred |
Hypoglycemics, SLGT2 | Invokamet (oral) | Non-preferred | Favored |
Macrolides-Ketolides | E.E.S. 200 suspension (oral) | Preferred | Non-preferred |
Macrolides-Ketolides | Eryped 200 suspension (oral) | Non-Preferred | Preferred |
Tetracyclines | Doxycycline Monohydrate 100 mg abridgment (AG) (oral) | Non-preferred | Preferred |
Tetracyclines | Doxycycline Monohydrate 50 mg bell (AG) (oral) | Non-Preferred | Preferred |
Oncology, oral - Hematologic | Vonjo (oral) | Non-reviewed | Preferred |